The treatment of multiple myeloma has advanced considerably in recent years with Celgene’s Revlimid and Janssen / Takeda Pharmaceutical’s Velcade remaining  key cornerstones of treatment. Janssen’s targeting antibody, Darzalex, has gained numerous label expansions and experienced rapid uptake since its initial 2015 approval. Amgen’s Kyprolis and Takeda’s Ninlaro are both approved for relapsed/refractory (R/R) multiple myeloma, and both have generated considerable physician interest. The plethora of regimens used to treat multiple myeloma poses decision-making challenges both in the clinic and in drug development.

Questions Answered 

  • What uptake have Darzalex-based and Pomalyst-based regimens experienced in the treatment of R/R symptomatic multiple myeloma, according to surveyed hematologist-oncologists?
  • What is the patient share of key therapies and regimens used to treat newly diagnosed and R/R multiple myeloma?
  • How do drug-treatment rates vary between key multiple myeloma patient segments according to stage of disease and line of therapy?
  • What drivers and obstacles influence treatment decisions in the newly diagnosed symptomatic multiple myeloma setting for select key regimens?

Product Description

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

Markets covered:  United States.

Primary research: Survey of 102 hematologist-oncologists in the United States fielded in January 2019.

Key drugs covered: Revlimid, Pomalyst, Velcade, Kyprolis, Darzalex, Empliciti, Ninlaro, Farydak.

Table of contents

  • Detailed, Expanded Analysis (US)
    • Current Treatment Physician Insights Multiple Myeloma US [May 2019]

Author(s): Priti Girotra, M.Pharm., Ph.D

Priti Girotra, , is an analyst in the oncology team at Decision Resources Group and has authored insightful content on multiple indications including Non-Small-Cell Lung Cancer, Colorectal Cancer, Gastroesophageal Cancer, Malignant Melanoma, and Multiple Myeloma. Prior to joining DRG, Dr. Girotra conducted her research on formulation optimization of nanoparticles containing triptan derivatives for effective brain targeting and therapeutic management of migraine, under a DST-INSPIRE Fellowship at University of Science & Technology, Hisar, India.


Related Reports

Multiple Myeloma | Landscape & Forecast | Disease Landscape & Forecast

Market Outlook The availability of premium-priced branded agents prescribed in doublet, triplet, and quadruplet regimens, particularly Darzalex-based therapies, has ...

View Details

Multiple Myeloma | Geographic Focus: China | Multiple Myeloma | China In-Depth | China

MARKET OUTLOOK Multiple myeloma is an incurable hematological malignancy with a 100% mortality rate that affects a sizeable Chinese population every year. With the intro...

View Details

Multiple Myeloma | Disease Landscape and Forecast | G7 | 2019

Market Outlook The multiple myeloma landscape is witnessing successive label expansions. The availability of premium-priced branded agents prescribed in not just doublet an...

View Details

Multiple Myeloma | Access & Reimbursement | Detailed, Expanded Analysis (US)

MARKET OUTLOOK Successive label expansions in the multiple myeloma treatment landscape are driving significant commercial reward for some well-entrenched current therapi...

View Details